There is a high incidence of women suffering from Primary Ovarian Insufficiency (POI). One of the most common treatments for POI is hormone replacement therapy (HRT), but HRT doesn't work well, and it has been shown to increase the risk of blood clots in the veins, ovarian cancer, and breast cancer. The ability of MSCs to differentiate into oocyte-like cells has been previously documented. Herein the purpose of this work is to evaluate the therapeutic potential of cell therapy in women suffering from POI.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
320
Intraovarian injection of placebo through vagina under the guidance of ultrasonic.
Intraovarian injection of HUC-MSCs through vagina under the guidance of ultrasonic.
Institute of Zoology, Chinese Academy of Sciences.
Beijing, Beijing Municipality, China
RECRUITINGNumber of mature follicle
The number of mature follicles developing was recorded by transvaginal ultrasound scan
Time frame: Up to 4 months
Follicle-stimulating hormone (FSH) serum level
Serum FSH level was evaluated once a month after surgery
Time frame: Up to 4 months
Estradiol (E2) serum level
Serum E2 level was evaluated once a month after surgery
Time frame: Up to 4 months
Anti-Mullerian hormone (AMH) serum level
Serum AMH level was evaluated once a month after surgery
Time frame: Up to 4 months
Number of antral follicle development
The number of antral follicles developing was recorded by transvaginal ultrasound scan
Time frame: Up to 4 months
Ovarian volume
The ovarian volume was recorded by transvaginal ultrasound scan
Time frame: Up to 4 months
Pregnancy rate
The incidence of pregnancy following transfer of embryos produced from oocytes recovered from follicles developing was assessed by Serum Human Chorionic Gonadotropin (HCG) detection.
Time frame: Up to 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.